51st Annual Meeting of the EBMT congress coverage: Lymphoma (Part 1)

Stay up to date with the latest developments in lymphoma (Part 1) with our live social media coverage from the 51st Annual Meeting of the EBMT, March 30 –April 2, 2025, Florence, Italy.  

CONGRESS | #EBMT25 | PRESENTATION
Nicole Santoro, Santo Spirito Hospital presented a retrospective study evaluating the efficacy and safety of brexu-cel in elderly patients aged >70 years with R/R MCL (N=202).
Outcomes at 1 year: OS and PFS were 74% and 65%, respectively.… pic.twitter.com/QV9ffeItre

— Lymphoma Hub (@lymphomahub) April 2, 2025

CONGRESS | #EBMT25 | PRESENTATION
Shan Fu, Hospital Universitari i Politècnic La Fe presented preliminary results from a phase I study evaluating the safety and efficacy of autologous CD7 CAR T-cell therapy for the treatment of patients with R/R T-cell #lymphoma (N=10).
ORR was… pic.twitter.com/boLFum6ZSq

— Lymphoma Hub (@lymphomahub) April 2, 2025

CONGRESS | #EBMT25 | PRESENTATION @dvandersonrocha, São Paulo University presented a study comparing outcomes of tisa-cel vs axi-cel in elderly patients aged >70 years with DLBCL. N=1064,
Outcomes in tisa cel vs axi cel at 1-Year:
OS: 56% vs 63%
PFS: 37% vs 51%
Relapse… pic.twitter.com/WfQdYGCWDo

— Lymphoma Hub (@lymphomahub) April 2, 2025

CONGRESS | #EBMT25 | POSTER
Eugen Leung, @UHN, discusses a case study of severe CAR T-cell therapy related toxicity. The 67-year old patient with mantle cell lymphoma developed Grade 2 CRS within 48 hours post CAR T-cell therapy, followed by Grade 4 ICANS on Day 7 and development… pic.twitter.com/c4dLGzUtU6

— Lymphoma Hub (@lymphomahub) April 1, 2025

CONGRESS | #EBMT25 | POSTER
Liudmila Fedorova, Gorbacheva Research Institute, Pavlov University, shares results of a study comparing second-line (Group 1) versus third- or fourth-line auto-HSCT (Group 2) in patients with R/R classic Hodgkin lymphoma (N = 51) treated with immune… pic.twitter.com/bnNsgqDmVa

— Lymphoma Hub (@lymphomahub) April 1, 2025

CONGRESS | #EBMT25 | POSTER
Nicolás De Lucas Torres, Hospital Universitario Central de Asturias, Oviedo, Spain @uniovi_info, presents findings of a retrospective study assessing the role of inflammatory biomarkers in predicting response to CAR T-cell therapy in patients with… pic.twitter.com/GgEJgtuNhH

— Lymphoma Hub (@lymphomahub) April 1, 2025

CONGRESS | #EBMT25 | POSTER
Ana Benzaquén, Hospital Clinico Universitario de Valencia, Valencia, Spain, shares findings from a retrospective study evaluating infectious episodes in adult patients with R/R Non-Hodgkin lymphoma treated with axi-cel (N = 54). Infectious episodes… pic.twitter.com/l876p5ouQF

— Lymphoma Hub (@lymphomahub) April 1, 2025

CONGRESS | #EBMT25 | PRESENTATION
Jan Schröder, University Hospital Tubingen presented an update on the impact of prior B-cell directed immunotherapy on the outcome of CD19 CAR-T cell therapy in aggressive B-cell malignancies.
Follow our live feed for more updates:… pic.twitter.com/TQxHvGa87x

— Lymphoma Hub (@lymphomahub) April 1, 2025

CONGRESS | #EBMT25 | PRESENTATION
Philipp Berning @UK_Muenster discussed an update on the role of bridging therapy before CAR-T cell therapy in diffuse large B-cell #lymphoma.
Follow our live feed for more updates: https://t.co/fJoKaNsrCt#lymsm #MedicalCongress @TheEBMT pic.twitter.com/VJiw8EQmdV

— Lymphoma Hub (@lymphomahub) April 1, 2025

CONGRESS | #EBMT25 | PRESENTATION
Alberto Mussetti from Hospitalet de Llobregat discussed results from a retrospective multicenter study of Allo-HCT as consolidation therapy in patients with R/R B-NHL who were exposed to CD3-CCD20 bispecific antibodies.
2-Year NRM: 36%… pic.twitter.com/JKlNXq8nfv

— Lymphoma Hub (@lymphomahub) April 1, 2025